Key result
Ticagrelor and aspirin increased vein graft patency after coronary artery bypass grafting, although the clinical significance of this improvement remains uncertain.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
May support ticagrelor-aspirin for graft patency post-CABG; leaves open effects on clinical outcomes.
Saphenous vein graft is commonly used for coronary artery bypass grafting (CABG) surgery. The most frequent complication is the occlusion of the venous graft despite preventive antiplatelet therapy based on aspirin (1,2), so much so that 10% to 25% of them occlude within one year of CABG (3).
No takes yet. Share an insight, caveat, or question.
Zlotnik et al. (2018) studied this question. Ticagrelor and aspirin increased vein graft patency after coronary artery bypass grafting, although the clinical significance of this improvement remains uncertain.
Synapse has enriched 10 related papers. Consider them for comparative context: